SCIENTIFIC-PRACTICAL JOURNAL

| укр | рус |

 

 


No6(2) 2019

Back to the issue


DOI 10.37219/2528-8253-2019-6-28

Zhulai T, Zupanets I, Shebeko S, Yampolska K.
Nasal endoscopy prospectsin experimental rhinology: some aspects of enisamium iodide nasal spray effectiveness in rhinosinusitis
Zhulai Tetiana
National University of Pharmacy, Department of Clinical Pharmacology and clinical Pharmacy
Assistant
Non-profit municipal enterprise «City clinical hospital NO30» of Kharkiv city Council
ENT-doctor
Email: tszhulay2910@gmail.com
Orchid ID: https://orcid.org/0000-0002-6190-3137

Zupanets Igor
National University of Pharmacy
Head of Department of Clinical Pharmacology and clinical Pharmacy
MD, Professor
Email: igorzupanets@gmail.com
Orchid ID: https://orcid.org/0000-0003-1253-9217
Scopus Author ID: 6701429712
Researcher ID: R-4205-2017

Shebeko Sergii
National University of Pharmacy
Department of Clinical Pharmacology and clinical Pharmacy
PhD in Pharmacy, associate professor
Email: shebekosk@gmail.com
Orchid ID: https://orcid.org/0000-0001-9350-7588
Scopus Author ID: 15822997100
Researcher ID: F-5218-2017

Yampolska Kateryna
Non-profit municipal enterprise «City clinical hospital NO30» of Kharkiv city Council
PhD, ENT-surgeon
Email: ekatyampolskaya@gmail.com
Orchid ID: https://orcid.org/0000-0003-2959-4706

Abstract

Acute rhinosinusitis treatment and prevention is connected to the rational choice of drug dosage form, which will provide the therapeutic effect and the safety of a drug substance or a drug substance complex. Nasal spray with Enisamium Iodide can be used to nasal congestion relief in acute rhinosinusitis because the active substance has an anti-exudative action. Nasal endoscopy could be used in experimental rhinology as a method for direct pathology visualization and for evaluation of the effectiveness of test drugs.
Aim: To substantiate Enisamium Iodide (nasal spray) 10 mg/mL effectiveness on maxillary sinus ostium via nasal endoscopy in rabbits with experimental rhinosinusitis.
Methods: As a test object was used Enisamium Iodide (nasal spray). As a reference drug, we used BNO-101. Experimental rhinosinusitis was induced in the 1st day. On the 1st , 15th and 25th days in all groups (four groups, six rabbits in each group), we used nasal endoscopy and semi-quantitative assessment to the result objectivity.
Results: The total score in the intact control group was 0 (0÷0) on the 15th and 25th days (physiological state). The total score in the control pathology group was 2.0 (2.0÷2.0) and 2.0 (1.0÷2.0) (severe rhinosinusitis) respectively. The total score in Enisamium Iodide treated group was 2.0 (1.0÷2.0) (severe rhinosinusitis) and 0.0 (0.0÷1.0) (physiological state). The total score in BNO-101 treated group was 2.0 (1.0÷2.0) (severe rhinosinusitis) and 1.0 (1.0÷1.0) (mild rhinosinusitis).
Conclusions: Nasal endoscopy can be used as an informative visual method. Enisamium Iodide (nasal spray) has been shown a positive effect by endoscopic evaluation of maxillary sinus ostium and exceeded activity of the reference drug.

Keywords

experimental rhinosinusitis, maxillary sinus ostium, nasal endoscopy, Enisamium Iodide (nasal spray), effectiveness.


Reference

  1. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020 Feb 20;58 (Suppl S29): 1-464. doi: 10.4193/Rhin20.600.
  2. Koch AK, Klose P, Lauche R, Cramer H, Baasch J, Dobos GJ, et al. A Systematic Review of Phytotherapy for Acute Rhinosinusitis. Forsch Komplementmed. 2016; 23(3): 165-9. doi: 10.1159/000447467.
  3. Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012 Apr; 54(8): e72-e112. doi: 10.1093/cid/cir1043.
  4. [Unified clinical protocol for primary, secondary (specialized) and tertiary (highly specialized) care: acute rhinosinusitis]. Order of the Ministry of Health of Ukraine № 85, 11.02.2016. [In Ukrainian] Available from: https://dec.gov.ua/wpcontent/uploads/images/dodatki/2016_85_GRS/2016_85_YKPMD_GRS.pdf.
  5. Zhulai TS, Zupanets IA, Shebeko SK. [Investigation of dose dependence of anti-exudative action of a new nasal spray with anti-inflammatory properties]. Clinical Pharmacy, 2017; 21(4): 11-7. http://doi.org/10.24959/cphj.17.1446. [Article in Ukrainian].
  6. Zhulai TS. Preclinical study of a new nasal spray with anti-inflammatory properties: the effect on the leukotriene-induced inflammation. Clinical pharmacy. 2018; 22(4): 27-33. http://doi.org/10.24959/cphj.18.1473.
  7. Zhulai T, Shebeko S, Goy A. Perspectives for use of the new nasal spray with anti-inflammatory action in treatment of acute rhinosinusitis. Rhinology. 2018;56(Suppl 27): S585.
  8. Cohen-Kerem R, Marshak T, Uri N, Gruber M, Huberfeld O, Paz D, et al. Is Nasal Endoscopy of Diagnostic Value in Chronic Rhinosinusitis Without Nasal Polyps? Ear Nose Throat J. 2019 Sep 23:145561319864578.
    doi: 10.1177/0145561319864578.
  9. Wuister AM, Goto NA, Oostveen EJ, de Jong WU, van der Valk ES, Kaper NM, et al. Nasal endoscopy is recommended for diagnosing adults with chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2014 Mar; 150(3): 359-64.
    doi: 10.1177/0194599813514510.
  10. Colley P, Mace JC, Schaberg MR, Smith TL, Tabaee A. Impact of educational intervention on the interrater agreement of nasal endoscopy interpretation. Laryngoscope. 2015 Oct; 125(10): 2259-65. doi: 10.1002/lary.25240.
  11. Turner PV, Pekow C, Vasbinder MA, Brabb T. Administration of substances to laboratory animals: equipment considerations, vehicle selection, and solute preparation. J Am Assoc Lab Anim Sci. 2011 Sep;50(5):614-27.
  12. Guidance lor industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials lor Therapeutics in Adult Healthy Volunteers. 2005. Available from: https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/
    estimating-maximum-safe-starting-dose-initialclinical-trials-therapeutics-adult-healthy-volunteers.
  13. [On state registration (re-registration) of medicinal products (medical immunobiological preparations) and amendments to registration materials. Ministry of Health of Ukraine, Order No. 509 of May 12, 2017]. Available from: http://search.ligazakon.ua/l_doc2.nsf/link1/MOZ27507.html. [In Ukrainian].
  14. Flecknell PA, editor. Laboratory Animal Anesthesia. 4th ed. Oxford: Academic Press; 2015. 350 p.
    Available from: http://dx.doi.org/10.1016/C2013-0-13494-0.
  15. Perez AC, Buzatto GP, Dantas I de P, Dorgam JV, Valera FC, Tamashiro E, et al. [Review of experimental models: sinusitis in rabbits]. Braz J Otorhinolaryngol. 2014 Sep-Oct; 80(5): 435-40. doi: 10.1016/j.bjorl.2014.07.011. [Article in Portuguese].
  16. Costa HO, Ruschi e Luchi GE, Augusto AG, Castro M, de Souza FC. Comparative study of several sinusitis experimental modeling techniques in rabbits. Braz J Otorhinolaryngol. 2007 Sep-Oct; 73(5): 627-31.
    doi: 10.1016/s1808-8694(15) 30122-1.
  17. OECD Series on principles of good laboratory practice and compliance monitoring Number 20 Guidance Document for Receiving Authorities on the Review of the GLP Status of NonClinical Safety Studies. ENV/JM/MONO(2019)25. Available from: http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV-JM-MONO(2019)25%20&doclanguage=en.
  18. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Med Etika Bioet. 2002 Spring-Summer; 9(1-2): 12-9.
  19. Islam MA, Al-Shiha A. Foundations of Biostatistics. Springer. 2018. 474 p.
  20. Quirk T, Quirk MH, Horton HF. Excel 2016 for Biological and Life Sciences Statistics. Springer International Publishing: Switzerland; 2016.
 

© 2019, Public Organization «Ukrainian Scientific Medical Society of Otorhinolaryngologists»